FY2023 EPS Estimates for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Cut by Leerink Partnrs

Agios Pharmaceuticals, Inc. (NASDAQ:AGIOFree Report) – Equities research analysts at Leerink Partnrs reduced their FY2023 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report issued on Monday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biopharmaceutical company will earn ($6.30) per share for the year, down from their previous forecast of ($6.29). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.25) per share. Leerink Partnrs also issued estimates for Agios Pharmaceuticals’ Q4 2023 earnings at ($1.69) EPS, Q1 2024 earnings at ($1.69) EPS, Q2 2024 earnings at ($1.71) EPS, FY2024 earnings at ($6.27) EPS, FY2025 earnings at ($6.20) EPS and FY2026 earnings at ($4.84) EPS.

Separately, The Goldman Sachs Group lowered their price objective on Agios Pharmaceuticals from $32.00 to $28.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd.

Get Our Latest Analysis on Agios Pharmaceuticals

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $23.69 on Thursday. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $30.86. The stock has a 50-day simple moving average of $22.89 and a 200-day simple moving average of $23.86. The firm has a market cap of $1.32 billion, a P/E ratio of -6.00 and a beta of 0.76.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of AGIO. China Universal Asset Management Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 96.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 700 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $39,000. Tower Research Capital LLC TRC grew its holdings in shares of Agios Pharmaceuticals by 53.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,478 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 864 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Agios Pharmaceuticals by 37.9% in the 1st quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 805 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Agios Pharmaceuticals by 9.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,587 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 387 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Brian Goff sold 12,066 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $22.99, for a total value of $277,397.34. Following the sale, the chief executive officer now owns 40,053 shares of the company’s stock, valued at approximately $920,818.47. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Agios Pharmaceuticals news, CEO Brian Goff sold 12,066 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $22.99, for a total transaction of $277,397.34. Following the sale, the chief executive officer now owns 40,053 shares of the company’s stock, valued at approximately $920,818.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jacqualyn A. Fouse sold 8,391 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $22.99, for a total value of $192,909.09. Following the sale, the director now directly owns 116,075 shares in the company, valued at approximately $2,668,564.25. The disclosure for this sale can be found here. Insiders have sold a total of 46,473 shares of company stock valued at $1,036,836 in the last quarter. Insiders own 4.24% of the company’s stock.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias.

See Also

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.